2. UroToday Home
  3. Transformative Evidence

Transformative Evidence

The RALU Study: Treatment Considerations in the First Line Setting of mCRPC

Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos
Publications
Commentaries that look beyond the published abstracts

The RAdium LUtetium (RALU) study evaluated the feasibility of sequential alpha and beta emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer.

This pre-planned, interim, retrospective analysis investigated safety and survival outcomes with lutetium-177-PSMA (177Lu-PSMA) in patients treated with prior radium-223 (223Ra).

Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Kambiz Rahbar, MD
On the first day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023 focussing on prostate cancer, Dr. Kambiz Rahbar presented data from the RALU trial in Poster Session A, examining the association between the time interval between sequential treatment with radium‑223 (223Ra) therapy and Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) and subsequent outcomes.
Presented by Kambiz Rahbar, MD
(UroToday.com) The 2022 ESMO annual meeting featured a prostate cancer session, including a presentation by Dr. Kambiz Rahbar discussing safety and effectiveness outcomes of 177Lu-PSMA therapy in patients with prior treatment with radium-223. Radium-223 is an established targeted alpha therapy with a good safety profile that prolongs overall survival (OS) and improves quality of life in patients with bone-predominant mCRPC.
Presented by Kambiz Rahbar, MD
(UroToday.com) At the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, the poster session focused on Prostate, Testicular, and Penile cancers on Monday afternoon included a presentation from Dr. Kambiz Rahbar discussing sequential treatment with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra) in men with metastatic castration-resistant prostate cancer (mCRPC).